JP2016501515A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501515A5
JP2016501515A5 JP2015539804A JP2015539804A JP2016501515A5 JP 2016501515 A5 JP2016501515 A5 JP 2016501515A5 JP 2015539804 A JP2015539804 A JP 2015539804A JP 2015539804 A JP2015539804 A JP 2015539804A JP 2016501515 A5 JP2016501515 A5 JP 2016501515A5
Authority
JP
Japan
Prior art keywords
composition
animal
stem cell
vector
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066651 external-priority patent/WO2014066663A1/en
Publication of JP2016501515A publication Critical patent/JP2016501515A/ja
Publication of JP2016501515A5 publication Critical patent/JP2016501515A5/ja
Priority to JP2018135886A priority Critical patent/JP6975105B2/ja
Pending legal-status Critical Current

Links

JP2015539804A 2012-10-24 2013-10-24 血小板標的化治療 Pending JP2016501515A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018135886A JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
US61/717,951 2012-10-24
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018135886A Division JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Publications (2)

Publication Number Publication Date
JP2016501515A JP2016501515A (ja) 2016-01-21
JP2016501515A5 true JP2016501515A5 (enExample) 2016-11-10

Family

ID=50545271

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015539804A Pending JP2016501515A (ja) 2012-10-24 2013-10-24 血小板標的化治療
JP2018135886A Active JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018135886A Active JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Country Status (12)

Country Link
US (4) US9982034B2 (enExample)
EP (2) EP2912186B1 (enExample)
JP (2) JP2016501515A (enExample)
KR (1) KR101819803B1 (enExample)
BR (1) BR112015009229B1 (enExample)
CA (1) CA2888982C (enExample)
DK (1) DK2912186T3 (enExample)
ES (1) ES2854754T3 (enExample)
IL (1) IL238417B (enExample)
PL (1) PL2912186T3 (enExample)
WO (1) WO2014066663A1 (enExample)
ZA (1) ZA201502945B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011550A1 (en) 2015-07-13 2017-01-19 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
US20200291356A1 (en) * 2019-03-13 2020-09-17 Cellphire, Inc. Canine blood platelet preparations
EP3735457A4 (en) 2018-01-05 2021-08-25 Platelet Biogenesis, Inc. COMPOSITIONS AND METHODS FOR PRODUCING MEGACARYOCYTES
US12403161B2 (en) 2018-06-29 2025-09-02 Stellular Bio, Inc. Compositions for drug delivery and methods of use thereof
US20220033776A1 (en) * 2018-10-05 2022-02-03 University Of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
EP3887402A4 (en) 2018-11-30 2022-10-26 Cellphire, Inc. PLATELETS AS RELEASING AGENT
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
BR112021021984A2 (pt) 2019-05-03 2022-03-03 Cellphire Inc Materiais e métodos para produzir produtos de sangue
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
CA3170201A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ZA975326B (en) 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
JP4153999B2 (ja) 1996-12-20 2008-09-24 アルザ・コーポレーション 経皮作用剤流量を強化するための組成物と方法
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
EP1397496A2 (en) * 2001-06-15 2004-03-17 Andre Schuh Gene therapy for hemophilia a
DK1412493T3 (da) 2001-08-02 2012-01-09 Inst Clayton De La Rech Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
US20050238660A1 (en) 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
WO2012119103A2 (en) 2011-03-02 2012-09-07 Proteonomix, Inc. Compositions and methods for mobilization of stem cells

Similar Documents

Publication Publication Date Title
JP2016501515A5 (enExample)
Bi et al. Fusogenic micropeptide Myomixer is essential for satellite cell fusion and muscle regeneration
Abba et al. MicroRNA regulation of epithelial to mesenchymal transition
JP2016500260A5 (enExample)
JP2018522072A5 (enExample)
RU2021132734A (ru) Химерные рецепторы антигена, нацеленные на psca
Roato et al. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases
MX2020005282A (es) Vector para la produccion de particulas aav.
JP2015525065A5 (enExample)
BR112015019950A2 (pt) Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro
HRP20210057T1 (hr) Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2019508051A5 (enExample)
RU2020103811A (ru) Гуманизированные животные по с5 и с3
EA201401319A1 (ru) Способы и композиции рнк-специфической модификации днк-мишении рнк-специфической модуляции транскрипции
CN107794272A (zh) 一种高特异性的crispr基因组编辑体系
EA201590488A1 (ru) Способы модификации клеток-хозяев
JP2016518142A5 (enExample)
JP2012065652A5 (enExample)
JP2017536826A5 (enExample)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA201690355A1 (ru) Инсектицидные полипептиды с широким спектром активности и их применения
UA115235C2 (uk) Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування
IL269187B1 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
EA201691192A1 (ru) Гены токсинов axmi477, axmi482, axmi486 и axmi525 и способы их применения